AFFILIATIONS
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
10 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
11 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
12 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
ABSTRACT
Objective: Although European LeukemiaNet (ELN) risk stratification and IDH mutations have prognostic value in cytogenetically normal acute myeloid leukemia (CN-AML), the clinical outcomes of IDH-mutated patients remain heterogeneous. The role of LILRB3 gene mutations in this specific subgroup has not been characterized. This study aimed to investigate the incidence and prognostic value of LILRB3 gene mutations in IDH1/2-mutant CN-AML patients.
Methods: Bone marrow samples were collected from 103 newly diagnosed IDH1/2-mutant CN-AML patients at Peking University People's Hospital from September 2007 to December 2019. The cohort had a median age of 49 years (range, 17–69), with 63 males (61.2%) and 40 females (38.8%). LILRB3 mutations were detected by Sanger sequencing using 6 primer pairs covering the coding region. Cumulative incidence of relapse (CIR) and relapse-free survival (RFS) were calculated using the Kaplan–Meier method, with between-group comparisons performed using the log-rank test. Multivariable analysis was conducted using the Cox proportional hazards regression model to evaluate the independent impact of LILRB3 mutations on prognosis, adjusting for age, white blood cell (WBC) count, and common gene mutations including FLT3-ITD, NPM1, and DNMT3A.
Results: Among the 103 patients, 11 (10.7%) carried LILRB3 mutations, with 8 distinct mutation types identified, including 6 missense mutations (A–F), 1 in-frame indel mutation (G), and 1 in-frame insertion mutation (H). Baseline characteristics were well balanced between the LILRB3-mutated and wild-type groups, with no significant differences in age, sex, French-American-British (FAB) subtype, WBC count, hemoglobin, platelet count, bone marrow blast percentage, transplant rate, or IDH1/IDH2 mutation distribution. Univariate analysis demonstrated that the mutated group had a significantly higher 5-year CIR (68.2% vs. 38.0%, P=0.043) and significantly lower 5-year RFS (15.9% vs. 24.8%, P=0.005) compared with the wild-type group. Multivariable Cox regression analysis confirmed that LILRB3 mutation was an independent risk factor for CIR (HR=3.08, 95% CI 1.12–8.51, P=0.03) and RFS (HR=3.63, 95% CI 1.5–8.8, P=0.004), independent of ELN risk stratification and other common mutations.
Conclusion: LILRB3 mutation is independently associated with increased relapse risk and shortened survival in IDH1/2-mutant CN-AML patients. Unlike prior studies focusing on LILRB3 expression levels, our findings extend the prognostic relevance to the genetic level. As an immune checkpoint receptor, LILRB3 shares functional similarities with other LILRB family members in myeloid malignancies, yet its mutation-specific impact appears distinct. These results suggest that LILRB3 mutation may serve as a novel prognostic biomarker for this subgroup, refining risk stratification, guiding personalized therapy, and providing a rationale for LILRB3-targeted immunotherapy.
DISCLOSURES
Yao Jiao: No relevant conflicts of interest to declare.